cagrisema phase 3 results 2025 cagrilintide semaglutide obesity 2024 Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide Novo Nordisk's next-gen obesity drug
Novo Nordisk's next gen obesity drug CagriSema trial results disappoint investors CagrilintideSemaglutide in Adults with Overweight or Obesity and Type 2 Diabetes New England Journal of Medicine Novo Nordisk to present array of new portfolio data including studies with semaglutide and CagriSema, expanding evidence in obesity and diabetes care at ADA 2025 Novo Nordisk presents new Phase III data for next gen amylin cagrilintide The Pharmaletter Coadministered Cagrilintide and Semaglutide, in Adults with Overweight or Obesity. June 22,, 2025. DOI: 10.1056 NEJMoa2502081, CagrilintideSemaglutide in Adults with, Overweight or Obesity and Type 2
Pay in 4 interest-free payments of $6.84 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6



